How to Help Your Patients Find Zurzuvae In Stock: A Provider's Guide

Zurzuvae (zuranolone) is the only FDA-approved oral treatment for postpartum depression—and for the right patient, it can make a meaningful difference. But the specialty pharmacy distribution model, prior authorization requirements, and patient support workflow mean your team must navigate a process that's substantially different from writing a standard antidepressant prescription.

This guide is a practical, step-by-step playbook for providers and their care teams to help PPD patients access Zurzuvae as efficiently as possible in 2026.

Step 1: Confirm Patient Eligibility and Clinical Appropriateness

Before initiating the specialty pharmacy process, confirm that Zurzuvae is clinically appropriate for your patient:

• PPD diagnosis meeting DSM criteria for major depressive episode with onset in the third trimester or within 4 weeks postpartum (ACOG recommends consideration within 12 months of delivery for severe cases)
• Patient is not pregnant (Zurzuvae may cause fetal harm; effective contraception required during treatment and for 1 week after)
• Childcare plan in place: patients should not drive or operate heavy machinery for at least 12 hours after each evening dose—this may affect their ability to care for the infant and other children
• No history of hypersensitivity to zuranolone or its excipients
• Review substance use history (Schedule IV controlled substance; elevated risk in patients with history of substance use disorder)

Step 2: Verify Insurance and Identify the Right Specialty Pharmacy

Your patient's insurance will usually dictate which specialty pharmacy they must use. Before submitting the prescription, have a staff member:

1. Call the patient's insurance to verify Zurzuvae is covered and identify in-network specialty pharmacies
2. OR call Sage Central (1-844-987-9882)—they can perform a benefit investigation and identify appropriate specialty pharmacies
3. OR use medfinder to quickly identify which specialty pharmacies are able to fill the prescription

Step 3: Submit a Complete Prior Authorization

Most plans require prior authorization. An incomplete PA is the most common cause of delay. A strong PA submission includes:

• Correct ICD-10 code: F53.0 (postpartum depression). Do not use a generic MDD code.
• Clinical documentation: HAMD-17 or Edinburgh Postnatal Depression Scale (EPDS) score, symptom onset timing (third trimester or within 4 weeks postpartum), and severity classification.
• Prior therapy documentation: If step therapy applies, document any prior antidepressant trials, responses, and reasons for discontinuation or inadequate response.
• Clinical urgency: For patients with severe PPD, suicidal ideation, or impaired maternal-infant bonding, document the clinical need for Zurzuvae's rapid onset mechanism.

Submit via CoverMyMeds or the plan's specific PA portal. After submission, follow up if you haven't heard back within 3 business days.

Step 4: Set Patient Expectations and Prepare the Care Plan

Counsel your patient that:

• The specialty pharmacy will call (and possibly text) twice—to verify insurance and to coordinate shipment. Emphasize adding the pharmacy number to their contacts.
• Zurzuvae is taken once daily in the evening with a fatty meal (to optimize absorption) for exactly 14 days.
• No driving or hazardous activities for at least 12 hours after each dose—arrange childcare support.
• Use contraception during treatment and for one week after the last dose.
• Some improvement may be noticeable by Day 3; the primary clinical endpoint in trials was Day 15.

38,440+ patients found their medications in stock

38K+

Find Zurzuvae In Stock Today →

Step 5: Enroll in Savings Programs

For patients with commercial insurance: enroll in the Zurzuvae Savings Card Program through Sage Central. Eligible patients may pay $0 out-of-pocket for the 14-day supply. This program is not available for patients with Medicare, Medicaid, or other government insurance.

For patients who are uninsured or underinsured: Sage offers a free drug program for qualifying patients. Sage Central can assess eligibility and enroll the patient.

Using medfinder as a Clinical Support Tool

medfinder can help your patients (and your care team) quickly identify which specialty pharmacies in your area are able to fill Zurzuvae prescriptions. Rather than spending staff time calling pharmacies one by one, medfinder automates this check and delivers results by text. For providers, medfinder's platform at medfinder.com/providers is designed to support exactly this kind of access challenge.

Skip the calls, skip the stress.

Find Zurzuvae In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

After the 14-Day Course: Planning Follow-Up

Schedule a follow-up visit around Day 15–21 to assess treatment response and ongoing needs. Clinical trial data shows that improvements seen at Day 15 were sustained through Day 45. However, Zurzuvae is not approved or studied for chronic long-term use. For patients who respond well, discuss whether continued antidepressant therapy is appropriate. For patients who don't achieve adequate remission, consider adding or transitioning to an SSRI or SNRI. See also: Zurzuvae Side Effects: What to Expect.